Moderna (MRNA) Tops Q1 EPS by 66c; offers guidance

Moderna (NASDAQ: MRNA) reported Q1 EPS of ($2.52), $0.66 better than the analyst estimate of ($3.18). Revenue for the quarter came in at $108 million versus the consensus estimate of $115.3 million.

GUIDANCE:

Moderna sees FY2025 revenue of $1.5-2.5 billion, versus the consensus of $2.13 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• JELD-WEN Expands Environmental Product Declaration Portfolio
• FedEx (FDX) call put ratio 1 call to 2.8 puts with a focus on June 26 weekly 325 puts into quarter results